Statin use and female reproductive organ cancer risk in a large population-based setting

Onchee Yu, Denise M. Boudreau, Diana S M Buist, Diana L Miglioretti

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objective: Statins are an effective and commonly used cholesterol-lowering medication class, but their hypothesized effects on cancer risk remain uncertain. We evaluated the association between statin use and endometrial as well as ovarian cancer risks. Methods: We conducted a retrospective study with two cohorts of women aged 45-89 years during 1990-2004 within an integrated healthcare delivery system. Information on statin use and covariates were obtained from automated databases. We identified cancer cases through the Surveillance, Epidemiology, and End Results registry. Multivariable Cox proportional hazards models were used to estimate the hazard ratios (HR) and 95% confidence intervals (CI) for incident invasive endometrial and ovarian cancers among statin users compared to nonusers. Results: Women were followed for a median of about six years. Among 73,336 women studied, 568 endometrial cancer cases were identified. During the study period, 6% of women used statins for at least one year and the median duration of use was 3.1 years. Although not statistically significant, we found a reduction in endometrial cancer risk among statin users (HR = 0.67; 95% CI: 0.39-1.17) compared to nonusers. We identified 326 ovarian cancer cases in a cohort of 93,619 women. There was also a nonsignificant decrease in ovarian cancer risk among statin users (HR = 0.69; 95% CI: 0.32-1.49). Conclusion: Our study does not support an association between statin use and endometrial as well as ovarian cancers, but a reduced risk cannot be ruled out.

Original languageEnglish (US)
Pages (from-to)609-616
Number of pages8
JournalCancer Causes and Control
Volume20
Issue number5
DOIs
StatePublished - Jul 2009
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Endometrial Neoplasms
Ovarian Neoplasms
Population
Neoplasms
Confidence Intervals
Integrated Delivery of Health Care
Delivery of Health Care
Proportional Hazards Models
Registries
Epidemiology
Retrospective Studies
Cholesterol
Databases

Keywords

  • Endometrial cancer
  • HMG-CoA reductase inhibitors
  • Ovarian cancer
  • Statins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Statin use and female reproductive organ cancer risk in a large population-based setting. / Yu, Onchee; Boudreau, Denise M.; Buist, Diana S M; Miglioretti, Diana L.

In: Cancer Causes and Control, Vol. 20, No. 5, 07.2009, p. 609-616.

Research output: Contribution to journalArticle

Yu, Onchee ; Boudreau, Denise M. ; Buist, Diana S M ; Miglioretti, Diana L. / Statin use and female reproductive organ cancer risk in a large population-based setting. In: Cancer Causes and Control. 2009 ; Vol. 20, No. 5. pp. 609-616.
@article{3bd6b97b1b4f4822b4b88304db7a35c5,
title = "Statin use and female reproductive organ cancer risk in a large population-based setting",
abstract = "Objective: Statins are an effective and commonly used cholesterol-lowering medication class, but their hypothesized effects on cancer risk remain uncertain. We evaluated the association between statin use and endometrial as well as ovarian cancer risks. Methods: We conducted a retrospective study with two cohorts of women aged 45-89 years during 1990-2004 within an integrated healthcare delivery system. Information on statin use and covariates were obtained from automated databases. We identified cancer cases through the Surveillance, Epidemiology, and End Results registry. Multivariable Cox proportional hazards models were used to estimate the hazard ratios (HR) and 95{\%} confidence intervals (CI) for incident invasive endometrial and ovarian cancers among statin users compared to nonusers. Results: Women were followed for a median of about six years. Among 73,336 women studied, 568 endometrial cancer cases were identified. During the study period, 6{\%} of women used statins for at least one year and the median duration of use was 3.1 years. Although not statistically significant, we found a reduction in endometrial cancer risk among statin users (HR = 0.67; 95{\%} CI: 0.39-1.17) compared to nonusers. We identified 326 ovarian cancer cases in a cohort of 93,619 women. There was also a nonsignificant decrease in ovarian cancer risk among statin users (HR = 0.69; 95{\%} CI: 0.32-1.49). Conclusion: Our study does not support an association between statin use and endometrial as well as ovarian cancers, but a reduced risk cannot be ruled out.",
keywords = "Endometrial cancer, HMG-CoA reductase inhibitors, Ovarian cancer, Statins",
author = "Onchee Yu and Boudreau, {Denise M.} and Buist, {Diana S M} and Miglioretti, {Diana L}",
year = "2009",
month = "7",
doi = "10.1007/s10552-008-9271-1",
language = "English (US)",
volume = "20",
pages = "609--616",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "5",

}

TY - JOUR

T1 - Statin use and female reproductive organ cancer risk in a large population-based setting

AU - Yu, Onchee

AU - Boudreau, Denise M.

AU - Buist, Diana S M

AU - Miglioretti, Diana L

PY - 2009/7

Y1 - 2009/7

N2 - Objective: Statins are an effective and commonly used cholesterol-lowering medication class, but their hypothesized effects on cancer risk remain uncertain. We evaluated the association between statin use and endometrial as well as ovarian cancer risks. Methods: We conducted a retrospective study with two cohorts of women aged 45-89 years during 1990-2004 within an integrated healthcare delivery system. Information on statin use and covariates were obtained from automated databases. We identified cancer cases through the Surveillance, Epidemiology, and End Results registry. Multivariable Cox proportional hazards models were used to estimate the hazard ratios (HR) and 95% confidence intervals (CI) for incident invasive endometrial and ovarian cancers among statin users compared to nonusers. Results: Women were followed for a median of about six years. Among 73,336 women studied, 568 endometrial cancer cases were identified. During the study period, 6% of women used statins for at least one year and the median duration of use was 3.1 years. Although not statistically significant, we found a reduction in endometrial cancer risk among statin users (HR = 0.67; 95% CI: 0.39-1.17) compared to nonusers. We identified 326 ovarian cancer cases in a cohort of 93,619 women. There was also a nonsignificant decrease in ovarian cancer risk among statin users (HR = 0.69; 95% CI: 0.32-1.49). Conclusion: Our study does not support an association between statin use and endometrial as well as ovarian cancers, but a reduced risk cannot be ruled out.

AB - Objective: Statins are an effective and commonly used cholesterol-lowering medication class, but their hypothesized effects on cancer risk remain uncertain. We evaluated the association between statin use and endometrial as well as ovarian cancer risks. Methods: We conducted a retrospective study with two cohorts of women aged 45-89 years during 1990-2004 within an integrated healthcare delivery system. Information on statin use and covariates were obtained from automated databases. We identified cancer cases through the Surveillance, Epidemiology, and End Results registry. Multivariable Cox proportional hazards models were used to estimate the hazard ratios (HR) and 95% confidence intervals (CI) for incident invasive endometrial and ovarian cancers among statin users compared to nonusers. Results: Women were followed for a median of about six years. Among 73,336 women studied, 568 endometrial cancer cases were identified. During the study period, 6% of women used statins for at least one year and the median duration of use was 3.1 years. Although not statistically significant, we found a reduction in endometrial cancer risk among statin users (HR = 0.67; 95% CI: 0.39-1.17) compared to nonusers. We identified 326 ovarian cancer cases in a cohort of 93,619 women. There was also a nonsignificant decrease in ovarian cancer risk among statin users (HR = 0.69; 95% CI: 0.32-1.49). Conclusion: Our study does not support an association between statin use and endometrial as well as ovarian cancers, but a reduced risk cannot be ruled out.

KW - Endometrial cancer

KW - HMG-CoA reductase inhibitors

KW - Ovarian cancer

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=67349221748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349221748&partnerID=8YFLogxK

U2 - 10.1007/s10552-008-9271-1

DO - 10.1007/s10552-008-9271-1

M3 - Article

VL - 20

SP - 609

EP - 616

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 5

ER -